Stable COPD in men was associated with significantly higher atherogenic indices, C-reactive protein, and triglycerides, and lower HDL cholesterol compared to healthy controls (P<0.05).
Case-Control (n=144)
Are atherogenic indices elevated in male subjects with stable COPD compared to healthy controls?
Atherogenic indices are significantly elevated in stable COPD patients compared to healthy controls and correlate negatively with FEV1, suggesting they may serve as useful predictors for atherosclerosis risk.
valor p: p=<.05
BACKGROUND: We aimed to investigate the predictor role of the plasma levels of lipid parameters and atherogenic indices on development of atherosclerosis in subjects with COPD. METHODS: We retrospectively analyzed 104 male subjects diagnosed with stable COPD in hospital records. We excluded subjects with exacerbation, with known cardiovascular diseases and other chronic diseases, receiving anti-hyperlipidemic treatment, without sufficient past medical history, and lacking needed laboratory data. Additionally, 40 age-matched male healthy controls were also enrolled. C-reactive protein, total cholesterol, triglycerides, low-density lipoprotein cholesterol, and high-density lipoprotein cholesterol levels of COPD and the control group were analyzed. Atherogenic indices (atherogenic index of plasma, cardiogenic risk ratio, and atherogenic coefficient) were calculated. RESULTS: C-reactive protein, triglyceride, atherogenic index of plasma, cardiogenic risk ratio, and atherogenic coefficient values were significantly higher in subjects with stable COPD than in control subjects ( P < .05 for all). High-density lipoprotein cholesterol level was significantly lower in subjects with COPD than in the control group ( P < .001). C-reactive protein, lipid profiles, and atherogenic indices were similar in lower-risk (stage A and B) and higher-risk (stage C and D) subjects with COPD. Cardiogenic risk ratio and atherogenic coefficient were negatively correlated with FEV 1 in all stable subjects with COPD and in higher-risk subjects with COPD (r = −0.27, P = .01 and r = −0.35, P = .01, respectively). CONCLUSIONS: We concluded that atherogenic indices (atherogenic index of plasma, cardiogenic risk ratio, atherogenic coefficient) could be considered as a useful predictor for atherosclerosis and cardiovascular diseases in stable COPD patients. Nevertheless, further prospective investigations on this issue are warranted.
Günay et al. (Tue,) conducted a case-control in COPD (n=144). Stable COPD vs. Healthy controls was evaluated on Atherogenic indices (atherogenic index of plasma, cardiogenic risk ratio, atherogenic coefficient), C-reactive protein, and lipid levels (p=<.05). Stable COPD in men was associated with significantly higher atherogenic indices, C-reactive protein, and triglycerides, and lower HDL cholesterol compared to healthy controls (P<0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: